文献速递骨软组织肉瘤与黑色素瘤

Talimogene laherparepvec联合帕博利珠单抗治疗晚期黑色素瘤的随机、双盲、安慰剂对照、全球III期试验

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
PubMed 文献 · J Clin Oncol · 2022-08-23

这项全球多中心III期随机双盲安慰剂对照试验纳入692例不可切除的IIIB-IVM1c期、未接受过抗PD-1治疗的晚期黑色素瘤患者,按1:1随机接受T-VEC联合帕博利珠单抗或安慰剂联合帕博利珠单抗治疗。联合组与对照组的无进展生存期(HR 0.86,95%CI 0.71-1.04,P=.13)和总生存期(HR 0.96,95%CI 0.76-1.22,P=.74)均无显著差异。结论是T-VEC联合帕博利珠单抗未显著改善PFS或OS,安全性结果与各单药的安全性特征一致。

要点

  • T-VEC联合帕博利珠单抗较安慰剂联合帕博利珠单抗未显著改善PFS(HR 0.86,95%CI 0.71-1.04,P=.13)。
  • T-VEC联合帕博利珠单抗较安慰剂联合帕博利珠单抗未显著改善OS(HR 0.96,95%CI 0.76-1.22,P=.74)。
  • 联合组≥3级治疗相关不良事件发生率为20.7%,安慰剂组为19.5%。

核心结论

  • T-VEC联合帕博利珠单抗较安慰剂联合帕博利珠单抗未显著改善PFS或OS,联合方案的安全性结果与各单药的安全性特征一致。

研究设计与样本

  • III期、随机、双盲、多中心、国际研究,比较T-VEC联合帕博利珠单抗与安慰剂联合帕博利珠单抗治疗晚期黑色素瘤。
  • 纳入不可切除的IIIB-IVM1c期黑色素瘤、未接受过抗程序性细胞死亡蛋白-1治疗的患者,按1:1随机分组。
  • 共692例患者随机分组:T-VEC联合帕博利珠单抗组346例,安慰剂联合帕博利珠单抗组346例。
  • T-VEC给药方案:首次≤4×10^6 PFU,3周后≤4×10^8 PFU,此后每2周一次至第5剂,之后每3周一次;帕博利珠单抗200 mg静脉给药,每3周一次。
  • 双主要终点为盲法独立中心评审按改良RECIST 1.1评估的PFS和OS;本次报告PFS的主要分析、OS的第二次预设 interim 分析和最终分析。

主要发现

  • T-VEC联合帕博利珠单抗组较安慰剂联合帕博利珠单抗组的PFS无显著改善(HR 0.86,95%CI 0.71-1.04,P=.13)。
  • T-VEC联合帕博利珠单抗组较安慰剂联合帕博利珠单抗组的OS无显著改善(HR 0.96,95%CI 0.76-1.22,P=.74)。
  • 客观缓解率:T-VEC联合帕博利珠单抗组48.6%(完全缓解率17.9%),安慰剂联合帕博利珠单抗组41.3%(完全缓解率11.6%)。
  • 持久缓解率:T-VEC联合帕博利珠单抗组42.2%,安慰剂联合帕博利珠单抗组34.1%。
  • ≥3级治疗相关不良事件发生率:T-VEC联合帕博利珠单抗组20.7%,安慰剂联合帕博利珠单抗组19.5%。

临床怎么用

  • 原文结论为T-VEC联合帕博利珠单抗较安慰剂联合帕博利珠单抗未显著改善PFS或OS,未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS: Patients with stage IIIB-IVM1c unresectable melanoma, naïve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab. T-VEC was administered at ≤ 4 × 106 plaque-forming unit (PFU) followed by ≤ 4 × 108 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter. Pembrolizumab was administered intravenously 200 mg once every 3 weeks. The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS). Secondary end points included objective response rate per mRECIST, CRR, and safety. Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis. RESULTS: Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab). T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab. The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively. Grade ≥ 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm. CONCLUSION: T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chesney JA, Ribas A, Long GV, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. J Clin Oncol. 2022. PMID: 35998300. doi:10.1200/JCO.22.00343

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。